FDA USE OF OUTSIDE PARTNERSHIPS
This article was originally published in The Gold Sheet
...is expanding to help meet the challenges of implementing a new quality review paradigm. The new collaborations are designed to help the Office of Pharmaceutical Science build a stronger knowledge base to support the agency’s Critical Path and 21st Century GMP initiatives. CRADAs have been reached with consultants to assess where firms are on the quality-by-design spectrum and how FDA can best support further progress and leverage the knowledge gained. A multi-university consortium is working with the agency to help fill the needs in basic manufacturing research and human resource development. Contract support is also being used by FDA to refine its own internal quality management system for the CMC review process. Meanwhile, research by a pair of academics has produced results which are helping FDA refine its risk-based inspection model and manufacturers better manage their quality practices.
You may also be interested in...
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.